Infiltration with ropivacaine plus lornoxicam reduces postoperative pain and opioid consumption

Basit Öğe Kaydı
dc.contributor.authorKaramanlioglu, B
dc.contributor.authorTuran, A
dc.contributor.authorMemis, D
dc.contributor.authorKaya, G
dc.contributor.authorOzata, S
dc.contributor.authorTure, M
dc.date.accessioned2024-06-12T11:18:39Z
dc.date.available2024-06-12T11:18:39Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To compare efficacy and patient outcome of wound infiltration with ropivacaine, lornoxicam, or their combination for control of pain following thyroid surgery. Methods: Eighty patients underwent thyroid surgery were randomly assigned to one of four groups. Before skin closure, local tissues were infiltrated with 12 mL saline in Group S, with 10 mL of ropivacaine 0.75% plus 2 mL saline in Group R, with 2 mL of lornoxicam (8 mg) plus 10 mL saline in Group L, and with 10 mL ropivacaine 0.75% plus 2 mL lornoxicam (8 mg) in Group RL. Pain scores, total and incremental meperidine consumption were recorded at 30 min, one, two, three, four, six, eight, 12, 18, and 24 hr postoperatively. Time to first analgesic requirement, patient satisfaction, and duration of hospital stay were also compared after surgery. Results: The pain scores in Group RL were significantly lower in the first 12 hr than in Group S, and in the first four hours than in Groups R and L (P<0.01). The time to first analgesic requirement was significantly longer (14.8 +/- 8.4 hr vs 5.9 +/- 5.2 hr; P<0.0 1), the total pethidine consumption was significantly less than Group S (34.0 +/- 33.0 mg vs 78.0 +/- 29.8 mg; P<0.001), return of gastrointestinal function, ambulation time, length of hospital stay (P<0.05) were significantly shorter, and patient satisfaction (P<0.01) was significantly better in Group RL than in Group S (P<0.05). Conclusion: Wound infiltration with ropivacaine 0.75% plus lornoxicam 8 mg combination improved postoperative pain control and patient comfort, and decreased the need for opioids than the use of either drug alone.en_US
dc.identifier.doi10.1007/BF03021603
dc.identifier.endpage1053en_US
dc.identifier.issn0832-610X
dc.identifier.issue10en_US
dc.identifier.pmid16326674en_US
dc.identifier.scopus2-s2.0-32044468038en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1047en_US
dc.identifier.urihttps://doi.org/10.1007/BF03021603
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24893
dc.identifier.volume52en_US
dc.identifier.wosWOS:000234240500007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCanadian Journal Of Anaesthesia-Journal Canadien D Anesthesieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectContinuous Wound Instillationen_US
dc.subjectThyroid-Surgeryen_US
dc.subjectBupivacaineen_US
dc.subjectAnalgesiaen_US
dc.subjectNauseaen_US
dc.subjectBlinden_US
dc.subjectPharmacokineticsen_US
dc.subjectDexamethasoneen_US
dc.subjectHysterectomyen_US
dc.subjectRequirementen_US
dc.titleInfiltration with ropivacaine plus lornoxicam reduces postoperative pain and opioid consumptionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu